• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Medtronic’s (MDT) Pain-Portfolio Pivot Offsetting Quality Scrutiny From Its Pediatric Cannula Recall?

    Simply Wall St·07/29/2026 14:17:44
    语音播报
    • In May 2026, Medtronic initiated a voluntary Class II recall of specific lots of its DLP One-Piece Pediatric Arterial Cannula after reports of loose foreign material containing trace blood, with the action now ongoing and affecting worldwide distribution including several US states.
    • At the same time, Medtronic has been reshaping its portfolio with the US$650 million SPR Therapeutics acquisition and ViaVerte pain system launch, adding non-opioid therapies alongside near-term quality and regulatory scrutiny from the cannula recall.
    • We’ll now examine how the ViaVerte pain launch and SPR Therapeutics acquisition influence Medtronic’s existing investment narrative and long-term growth thesis.

    This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

    Medtronic Investment Narrative Recap

    To own Medtronic, you need to believe its diversified devices portfolio and ongoing innovation can outweigh near term execution and regulatory risks. The Class II pediatric cannula recall adds to existing quality and margin concerns but, based on what we know today, does not appear large enough on its own to change the core thesis or the key near term catalyst, which remains evidence of improving margins as new platforms scale.

    The ViaVerte pain system launch and US$650 million SPR Therapeutics acquisition are particularly relevant, because they broaden Medtronic’s non opioid pain portfolio at the same time quality processes are under closer scrutiny after the cannula recall. How well Medtronic integrates SPR’s assets and executes on ViaVerte adoption could influence whether higher margin pain therapies help offset any ongoing cost or mix pressures in underperforming segments.

    Yet behind these opportunities, the bigger issue investors should also be aware of is how product quality events like this recall could intersect with...

    Read the full narrative on Medtronic (it's free!)

    Medtronic’s narrative projects $41.5 billion revenue and $6.6 billion earnings by 2029. This requires 4.5% yearly revenue growth and about a $1.8 billion earnings increase from $4.8 billion today.

    Uncover how Medtronic's forecasts yield a $98.00 fair value, a 13% upside to its current price.

    Exploring Other Perspectives

    MDT 1-Year Stock Price Chart
    MDT 1-Year Stock Price Chart

    Some of the lowest analysts paint a harsher picture, assuming revenue growth of only about 2% a year and earnings of roughly US$6.2 billion by 2029, so you should recognize that views on Medtronic’s recall exposure and growth platforms can differ widely and may shift again as this new information is absorbed.

    Explore 7 other fair value estimates on Medtronic - why the stock might be worth as much as 13% more than the current price!

    Decide For Yourself

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    • A great starting point for your Medtronic research is our analysis highlighting 5 key rewards that could impact your investment decision.
    • Our free Medtronic research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Medtronic's overall financial health at a glance.

    Interested In Other Possibilities?

    Our daily scans reveal stocks with breakout potential. Don't miss this chance:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.